Quick Facts

• Manages symptoms associated with: Allergic rhinitis
• Provides relief for: Bronchial asthma
• Assists in the management of: Chronic Obstructive Pulmonary Disorder (COPD)

---

Alerfix TOTAL is indicated for the therapeutic management of several respiratory conditions. It is used to provide relief from the symptoms associated with allergic rhinitis, commonly known as hay fever, which includes manifestations such as sneezing, runny nose, and itching.

This medication is also utilized in the sustained management of bronchial asthma by helping to maintain open airways. Furthermore, the combination is employed for supportive treatment in patients with chronic respiratory conditions, including Chronic Obstructive Pulmonary Disorder (COPD) and bronchitis.

Its action contributes to the loosening and thinning of mucus within the respiratory tract, which facilitates the process of coughing and helps to ease breathing. The primary role is to provide symptomatic relief and support the long-term control of these respiratory disorders.

Consultation with a qualified healthcare provider is essential to determine if this treatment is appropriate for a patient's specific medical profile.

Alerfix TOTAL is subject to formal restrictions based on age, organ function, and specific medical conditions, as defined by government regulatory agencies.

Contraindications and Prohibited Use

The medicine is contraindicated (must not be used) for the following populations:

• Patients with known hypersensitivity to Levocetirizine, Montelukast, Ambroxol, Cetirizine, or any product excipients.
• Individuals with severe renal impairment (creatinine clearance < 10 mL/min) or end-stage renal disease/anuria.
• Children aged 6 to 11 years with impaired renal function.
• Patients diagnosed with certain rare hereditary metabolic disorders (e.g., galactose intolerance).

Age-Related Eligibility and Conditional Use

Population	Eligibility Status (Regulatory Basis)
Adults and Adolescents	Generally indicated for patients 15 years and older (standard tablet formulation).
Children under 6 Years	Not recommended; safety and effectiveness for the tablet form are not established.
Pregnancy/Lactation	Not recommended during pregnancy and breastfeeding due to insufficient data or excretion into breast milk.

Conditional Use: The medicine requires caution in patients with mild to moderate hepatic or renal impairment (often requiring dose adjustment) and in those with predisposing factors for convulsions or urinary retention, as noted in official prescribing information.

Interactions with other medicines and products

This section describes officially documented interaction patterns between Alerfix TOTAL (Levocetirizine, Montelukast, Ambroxol) and other substances, as reported in regulatory prescribing information.

Pharmacokinetic and Pharmacodynamic Interactions

The co-administration of potent enzyme inducers such as Phenobarbital or Rifampicin is officially documented to cause a reduction in Montelukast plasma concentrations (exposure). Conversely, co-administration with Ritonavir is documented to result in an increase in Levocetirizine systemic exposure due to altered clearance mechanisms.

A documented pharmacodynamic interaction exists with alcohol and other Central Nervous System (CNS) depressants, which can cause additive impairment and should be avoided.

Interaction-Related Constraints

Interacting Substance/Class	Official Interaction Outcome/Restriction
Antitussives (e.g., Codeine)	Co-administration is officially noted as not recommended due to potential for excessive accumulation of respiratory secretions.
Antibiotics (Amoxicillin, Erythromycin)	Ambroxol is documented to increase the penetration of these antibiotics into lung tissues.
Food	Administration is permitted without regard to food; a high-fat meal may decrease peak concentration but overall exposure is not significantly affected.

Population-Specific Interaction Notes

The clearance of Levocetirizine is largely dependent on kidney function. In patients with renal impairment, a reduction in clearance and a corresponding increase in systemic exposure of Levocetirizine is a documented pharmacokinetic interaction.

Alerfix TOTAL is a fixed-dose combination product containing levocetirizine, montelukast, and ambroxol. Its systemic physiological modulation is achieved through three distinct, non-overlapping mechanisms.

Levocetirizine, a histamine H1 receptor inverse agonist, binds selectively to peripheral H1 receptors. This action decreases the constitutive activity of the receptor, thereby stabilizing it in an inactive conformation. The downstream consequence is the attenuation of Gq-protein signaling cascades that are typically initiated by the endogenous agonist, histamine.

Montelukast functions as a leukotriene receptor antagonist. It exhibits high affinity and selectivity for the cysteinyl leukotriene type 1 (CysLT1) receptor. By competitively binding to this receptor, montelukast blocks the physiological effects of endogenous cysteinyl leukotrienes ( LTC4, LTD4, and LTE4), preventing the activation of intracellular signaling pathways that mediate airway smooth muscle contraction and vascular permeability.

Ambroxol acts as a mucolytic agent through an effect on the viscosity of respiratory tract secretions. Its primary action involves the breakdown of acidic mucopolysaccharide fibers in mucus, decreasing the secretion's viscoelasticity. This systemic modulation results in the fragmentation of the mucus gel network.

Alerfix TOTAL is administered through the oral route as a fixed-dose combination tablet. The standard adult regimen involves the administration of one tablet once per day, which delivers the maximum daily maintenance dosages of the component agents. This once-daily administration pattern is aligned with the usage of the component drugs for the sustained management of chronic conditions.

Proper use is governed by a strict procedural requirement: the tablet must be swallowed whole with water. It is a fundamental condition that the tablet must not be chewed, crushed, or broken. This specific instruction is mandatory because the tablet includes a Sustained-Release (SR) component, and compromising its structure would disrupt its intended time-release profile.

The medicine may be taken independently of meals, allowing for flexible daily timing. However, the schedule often recommends daily dosing be initiated in the evening. This timing supports protocols for agents like Montelukast, aiming to provide control during nocturnal hours.

High-level population restrictions state that the fixed combination is generally not indicated for patients under 15 years of age. Furthermore, patients with documented impaired renal or hepatic function may require a dosage adjustment or increased caution based on the elimination characteristics of the Levocetirizine component. If a daily dose is missed, it is advised to omit the forgotten dose and resume the next scheduled dose as usual, strictly prohibiting the taking of a double dose.

Research Evidence / Overview of studies for Alerfix TOTAL

Evidence for Use in Allergic Rhinitis

Research examining the components of Alerfix TOTAL focuses heavily on its two primary anti-allergic components, levocetirizine and montelukast. This area has been evaluated through well-structured Randomized Controlled Trials (RCTs) and comprehensive systematic reviews, which are relevant in studies examining patient-reported experiences related to allergic rhinitis, a condition characterized by fluctuating or episodic manifestations. The findings describe patterns observed in these studies, where the dual combination was associated with observed differences in symptom scores when examined against either component alone. Comparative evidence for the full three-drug formula against established therapies is currently lacking.

---

Evidence for Use in Bronchial Asthma

Research examined the components of Alerfix TOTAL in studies that primarily focused on the levocetirizine and montelukast combination, especially in conditions involving periods of heightened symptoms. Studies examined how outcomes related to functional imbalance were affected, using specific objective measurements such as the Forced Expiratory Volume in 1 second ( FEV1) and patient-reported outcomes reflecting daily functioning. The data show patterns related to measured functional outcomes; however, the findings were mixed, with some research describing similar measurements in objective asthma parameters when comparing the dual combination to montelukast used by itself. Certainty remains low regarding the combination when severe, disruptive asthma episodes are examined.

---

Evidence for Use in Chronic Bronchitis and COPD Support

The research exploring Alerfix TOTAL in conditions marked by functional limitations such as chronic bronchitis and Chronic Obstructive Pulmonary Disorder (COPD) centers mainly on the third component, ambroxol, a mucolytic agent. Studies monitored outcomes describing episodic or acute changes, focusing on the frequency and duration of acute exacerbations (flare-ups) and the perceived difficulty of expectoration. Findings describe patterns observed in the studies, where studies monitored measured differences in the rate of acute exacerbations associated with mucolytics. The potential role of the anti-allergic components (levocetirizine and montelukast) in stable COPD is not fully established by regulatory research, leaving the overall evidence base for the full triple combination uncertain in this specific chronic disease population.

---

What is Still Uncertain About the Research

The primary uncertainty surrounds the overall evidence base for the triple combination itself; the majority of the high-level evidence supports the dual combination or the single mucolytic component individually, rather than the synergistic effect of all three together. Comparative evidence is lacking, and results apply only to the populations studied. Overall, long-term effects are not fully established, and data are still emerging regarding the combined clinical utility across all listed indications.

Key Studies & References

1. Montelukast: MedlinePlus Drug Information

Common questions about Alerfix TOTAL (FAQ)

---

Q: How quickly can someone expect to notice the effects of Alerfix TOTAL?

A: Regulatory summaries of the individual components generally describe the time it takes for drug levels to begin reaching concentrations associated with activity. Official information indicates that some components of this medicine have a rapid initial absorption rate. This profile suggests the potential for a quicker onset of action compared to agents without rapid absorption.

Q: How long does one dose of Alerfix TOTAL typically last?

A: The official administration instructions describe this medicine as a once-daily regimen. This schedule is specifically designed to provide sustained management of symptoms over a 24-hour period. Therefore, a single dose is intended to provide its effects for one full day.

Q: Is Alerfix TOTAL the type of medicine that needs to be taken every day?

A: Official guidance describes this medicine as a daily administration regimen intended for the sustained management of chronic conditions. This indicates that regular, consistent use over a period of time is often appropriate for the conditions the medicine is used for.

Q: What kind of studies support the claims made about Alerfix TOTAL?

A: The research evidence supporting the claims for the individual components is generally based on well-structured clinical studies. These include Randomized Controlled Trials (RCTs) and systematic reviews, which examined measured outcomes in the populations studied.

Q: Can people who are sensitive to specific inactive ingredients use Alerfix TOTAL?

A: Regulatory documents strictly state that this medicine is contraindicated (must not be used) in individuals who have a known hypersensitivity to any of the product’s excipients, which are the inactive ingredients. For this reason, official labels detail all components in the formulation.

Q: What if I forget a dose of Alerfix TOTAL—what is the general recommendation?

A: Official drug protocols advise that if a daily dose is missed, the user should omit the forgotten dose and continue with the next scheduled dose as usual. Taking a double dose to make up for the missed one is strictly prohibited by regulatory guidance.

Q: Can Alerfix TOTAL be used for skin allergies like hives, or only respiratory symptoms?

A: The anti-allergic components, such as levocetirizine, are described in official drug information for use in symptoms of conditions like chronic urticaria (hives). This indicates that the component's established uses include both skin and respiratory manifestations of allergy, depending on the regulatory approval for the combination.

Q: Are there documented cases of overdose symptoms for Alerfix TOTAL?

A: Regulatory documents for the active ingredients describe symptoms that have been observed in cases of overdose. These effects may relate to the individual components and can include issues such as drowsiness, agitation, and abdominal pain.

Q: Is it common to feel slightly dizzy when first taking Alerfix TOTAL?

A: Dizziness is documented in some official safety summaries as a reported side effect of the medicine. Like other commonly classified side effects, it may be experienced more often at the beginning of treatment.

Q: Do studies suggest Alerfix TOTAL is suitable for people with liver conditions?

A: Official prescribing information notes that the medicine requires caution in patients who have mild to moderate hepatic (liver) impairment. A dose adjustment may be required in these populations, based on the elimination profile of the component drugs.

Q: Are there any specific activities or machinery one should be cautious about while using Alerfix TOTAL?

A: Official safety information notes the potential for reduced alertness, which may be heightened when the medicine is used alongside alcohol or other CNS depressants. Therefore, caution is advised regarding activities that require full mental focus, such as operating machinery.

Q: Is Alerfix TOTAL available without a prescription in some countries?

A: The medicine is classified as a prescription-only (Rx) combination medicine. Official regulatory status and legal availability can vary depending on the specific country or region where it is sold.

Q: Why might a doctor prescribe Alerfix TOTAL instead of an over-the-counter option?

A: The formula combines three active components that target distinct mechanisms: allergic response, underlying inflammation, and mucus obstruction. This multi-component approach aims to address these three areas concurrently.

Q: Does regulatory information mention any specific mental health concerns linked to Alerfix TOTAL?

A: Regulatory documents highlight the requirement for caution regarding rare but serious neuropsychiatric events (events affecting the nervous system and mental state). These may include reports of aggression, agitation, or suicidal thinking and behavior, as documented with one of the components (Montelukast).

Q: What is the general age restriction for using Alerfix TOTAL?

A: The standard tablet formulation is generally indicated for use in patients 15 years of age and older. Use in patients younger than this age is usually not recommended for this specific combination tablet.

Q: Do health professionals generally consider Alerfix TOTAL for long-term use?

A: The medicine is prescribed as a daily regimen for the sustained management of chronic conditions. However, official regulatory documents also note that the overall long-term effects of the full triple combination are not fully established by the currently available research.

Q: Is the medication profile of Alerfix TOTAL different for older adults?

A: Official drug information advises that the medicine requires caution for older adults. This is primarily due to considerations around the body's processing of the drug, particularly the component (Levocetirizine) that is cleared by the kidneys.

Q: Is Alerfix TOTAL described as suitable for people with asthma?

A: The components of the medicine have been examined in studies that included patients with conditions like Bronchial Asthma. Research has looked at patient-reported outcomes and objective measurements like Forced Expiratory Volume in 1 second ( FEV1), although the evidence for the full triple combination's role is still emerging.

How to Store and Dispose of Alerfix TOTAL

The storage of Alerfix TOTAL tablets must strictly follow regulatory guidance to ensure product stability and safety. The official labeled requirement is to store the medicine in a cool, dry place at a temperature below 25°C or not exceeding 30°C. The product must be protected from both moisture and light and should not be frozen.

Child-Safety and Container Rules

The tablets must be kept in the original container, tightly closed. A mandatory safety precaution is to keep this medicine out of the sight and reach of children and pets.

Disposal Requirements

Expired or unused Alerfix TOTAL must be disposed of properly. Official guidelines advise using a drug take-back program when available. If a take-back program is not accessible, the product should be mixed with an undesirable substance and sealed before being placed in the household trash, ensuring it is not flushed down the toilet.